L M Waite1, G A Broe, D A Grayson, H Creasey. 1. Centre for Education and Research on Ageing, Concord Hospital C25, University of Sydney, NSW 2139, Australia. lwaite@medicine.usyd.edu.au
Abstract
OBJECTIVES: To identify if preclinical syndromes for Alzheimer's disease, vascular dementia, and Parkinson's disease and related dementias exist. Identification of dementia at early or even preclinical stages has important implications for treatment. METHODS: A community dwelling sample of 647 subjects aged 75 and over at recruitment were followed up for a mean period of 3.19 years (range 2.61 to 4.51 years). Each subject was asked to participate in a medical assessment which included a standardised medical history examining both past and current health and medication usage; a neuropsychological battery (mini mental state examination, Reid memory test, verbal fluency, subsets of the Boston naming test and similarities, clock drawing and copied drawings) and physical examination. Preclinical syndromes for the three predominant dementias (Alzheimer's disease, vascular dementia and Parkinson's disease, and related dementias) and their combinations were defined using cognitive, motor, and vascular features. Their longitudinal outcome as defined by death and dementia incidence was examined. RESULTS: Preclinical syndromes affected 55.7% (n=299) of subjects. Preclinical syndromes showed a trend for an increased odds of death (odds ratio 1.72, p=0.056) and a significantly increased odds of developing dementia (odds ratio 4.81, p<0.001). Preclinical syndromes were highly sensitive, detecting 52 of 58 (89.7%) incident dementias. Two hundred and sixteen of 268 (80.6%) preclinical subjects did not show dementia over the 3 year period (positive predictive value 19.4%). Subjects defined as having a combination of cognitive, extrapyramidal, and vascular features were at greatest risk of progressing to dementia. CONCLUSIONS: Preclinical syndromes were sensitive and significant predictors of dementia. In view of their poor positive predictive value, the preclinical syndromes as defined in this study remain a research tool needing both definitional refinement and greater periods of observation. Multiple coexistent preclinical disorders resulted in a greater incidence of dementia, providing evidence for an additive role between multiple disorders.
OBJECTIVES: To identify if preclinical syndromes for Alzheimer's disease, vascular dementia, and Parkinson's disease and related dementias exist. Identification of dementia at early or even preclinical stages has important implications for treatment. METHODS: A community dwelling sample of 647 subjects aged 75 and over at recruitment were followed up for a mean period of 3.19 years (range 2.61 to 4.51 years). Each subject was asked to participate in a medical assessment which included a standardised medical history examining both past and current health and medication usage; a neuropsychological battery (mini mental state examination, Reid memory test, verbal fluency, subsets of the Boston naming test and similarities, clock drawing and copied drawings) and physical examination. Preclinical syndromes for the three predominant dementias (Alzheimer's disease, vascular dementia and Parkinson's disease, and related dementias) and their combinations were defined using cognitive, motor, and vascular features. Their longitudinal outcome as defined by death and dementia incidence was examined. RESULTS: Preclinical syndromes affected 55.7% (n=299) of subjects. Preclinical syndromes showed a trend for an increased odds of death (odds ratio 1.72, p=0.056) and a significantly increased odds of developing dementia (odds ratio 4.81, p<0.001). Preclinical syndromes were highly sensitive, detecting 52 of 58 (89.7%) incident dementias. Two hundred and sixteen of 268 (80.6%) preclinical subjects did not show dementia over the 3 year period (positive predictive value 19.4%). Subjects defined as having a combination of cognitive, extrapyramidal, and vascular features were at greatest risk of progressing to dementia. CONCLUSIONS: Preclinical syndromes were sensitive and significant predictors of dementia. In view of their poor positive predictive value, the preclinical syndromes as defined in this study remain a research tool needing both definitional refinement and greater periods of observation. Multiple coexistent preclinical disorders resulted in a greater incidence of dementia, providing evidence for an additive role between multiple disorders.
Authors: I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg Journal: Lancet Date: 1996-04-27 Impact factor: 79.321
Authors: T Hanninen; K Koivisto; K J Reinikainen; E L Helkala; H Soininen; L Mykkänen; M Laakso; P J Riekkinen Journal: Age Ageing Date: 1996-05 Impact factor: 10.668
Authors: D A Bennett; L A Beckett; A M Murray; K M Shannon; C G Goetz; D M Pilgrim; D A Evans Journal: N Engl J Med Date: 1996-01-11 Impact factor: 91.245
Authors: T C Lye; D A Grayson; H Creasey; O Piguet; H P Bennett; L J Ridley; J J Kril; G A Broe Journal: Neuroradiology Date: 2005-12-20 Impact factor: 2.804
Authors: Olivier Piguet; Jane Cramsie; Hayley P Bennett; Jillian J Kril; Tanya C Lye; Alastair J Corbett; Michael Hayes; Helen Creasey; G Anthony Broe Journal: Eur Arch Psychiatry Clin Neurosci Date: 2006-08-17 Impact factor: 5.270
Authors: Joe Verghese; Aaron LeValley; Charles B Hall; Mindy J Katz; Anne F Ambrose; Richard B Lipton Journal: J Am Geriatr Soc Date: 2006-02 Impact factor: 5.562
Authors: T C Lye; O Piguet; D A Grayson; H Creasey; L J Ridley; H P Bennett; G A Broe Journal: J Neurol Neurosurg Psychiatry Date: 2004-04 Impact factor: 10.154
Authors: Darren M Lipnicki; Perminder S Sachdev; John Crawford; Simone Reppermund; Nicole A Kochan; Julian N Trollor; Brian Draper; Melissa J Slavin; Kristan Kang; Ora Lux; Karen A Mather; Henry Brodaty Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: Perminder S Sachdev; Darren M Lipnicki; John Crawford; Simone Reppermund; Nicole A Kochan; Julian N Trollor; Wei Wen; Brian Draper; Melissa J Slavin; Kristan Kang; Ora Lux; Karen A Mather; Henry Brodaty Journal: PLoS One Date: 2013-03-27 Impact factor: 3.240
Authors: Sam T Creavin; Susanna Wisniewski; Anna H Noel-Storr; Clare M Trevelyan; Thomas Hampton; Dane Rayment; Victoria M Thom; Kirsty J E Nash; Hosam Elhamoui; Rowena Milligan; Anish S Patel; Demitra V Tsivos; Tracey Wing; Emma Phillips; Sophie M Kellman; Hannah L Shackleton; Georgina F Singleton; Bethany E Neale; Martha E Watton; Sarah Cullum Journal: Cochrane Database Syst Rev Date: 2016-01-13